AstraZeneca drops an OX40 cancer drug candidate in Q4 pipeline cleanup
Q4 may have been a triumph in many respects, as AstraZeneca’s cancer drugs continue to carve out a bigger franchise for the company — crucial for its future. But there were also some big setbacks as the R&D group continues to hit and miss with its trials.
The biggest pipeline setbacks came with the failure of Imfinzi and tremelimumab in two combo studies aimed at lung and head and neck cancer, which we reported earlier.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.